Navigation Links
Valensa Completes Second Expansion of Astaxanthin Capacity
Date:4/14/2009

"Made in USA" label and allergen-free status of extracted product driving demand

ORLANDO, Fla., April 14 /PRNewswire/ -- Valensa International announced that it has completed a second round of expansion for astaxanthin production at its Eustis, Florida facility. The move was made in light of growing demand for a high-quality astaxanthin from North America that is both pesticide-free and allergen-free -- two conditions that are only possible with carefully controlled raw material monitoring and extraction facilities that are not used for extractions of materials that are known to cause allergic reactions, such as legumes and shellfish. The company announced a 20% expansion of capacity in February 2008. With the new capacity, Valensa is now producing 40% more of its ZANTHIN(R) natural astaxanthin extract than it did in 2007.

According to Dr. Rudi E. Moerck, President and CEO of Valensa, the recent expansions have come as a result of rapidly increasing demand in Europe for astaxanthin for eye health formulations, but have also been fueled by European and U.S.-based companies needing to establish a clear country of origin for their astaxanthin products as well as assuage concerns about potential contamination by allergenic materials. "Right now, Valensa International is the only company in the market who manufactures -- or extracts -- astaxanthin oleoresin in the United States. As a fully integrated supplier of astaxanthin, our customers can rely on where their product gets made," Moerck said. "When marketers of natural astaxanthin contract out for the extraction of biomass to produce natural astaxanthin, there is a chance that the extracting company will process multiple raw materials through the same facilities. We have seen instances in the market where materials such as shellfish are produced in the same facilities as astaxanthin and are sold without appropriate label warnings introducing the possibility of allergenicity into the final astaxanthin extract. Companies who work with Valensa are assured that cross-contamination of this type does not exist, and as a result, have chosen a fully integrated solution from sourcing algae biomass, to CO2 extraction and standardization," he added.

Made in the USA

Valensa's ZANTHIN(R) natural astaxanthin is an ultra-high pressure supercritical CO2 extraction of Haematococcus pluvialis freshwater algae that uses no chemical solvents. Valensa is the only fully integrated supplier of natural astaxanthin extract in the U.S. It is made to cGMP standards in a certified organic facility in Florida and the product is protected with Valensa's all-natural, proprietary O2B(R) stabilization technology which provides extra stability in storage, efficacy and in customer's formulations. Valensa's approach to manufacturing ensures the highest-quality, most consistent product on the market -- and recommends it for eye health and for its potent anti-oxidant properties.

"Quality is critical to the acceptance of astaxanthin in all product formulations especially eye health formulas. At Valensa, we are committed to providing the highest-quality astaxanthin on the market," said Moerck.

    For further information, contact:

    Dr. Rudi Moerck, President and CEO
    Voice: 352-357-2004 ext. 701
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
2. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
3. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
4. Pacer Health Corporation Successfully Completes Assignment of $11.7 Million in Convertible Debentures
5. Metropolitan Nashville Hospital Authority Completes Voice and Data Upgrade with tw telecoms Network Solutions
6. Aegis Living Completes Purchase of Real Estate in Aptos
7. AMICAS Successfully Completes Tender Offer for Shares of Emageon Inc.
8. DST Systems, Inc. Completes Acquisition of Remaining 50% of Argus Health Systems, Inc.
9. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Immunotech Completes Merger Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will ... States for the asthma & allergy friendly mark. This certification program was created by ... identify consumer products to be more suitable for the 60+ million people living in ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation Commission for Health ... its specialty care services. Albertsons Companies is the largest national food and ... pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment to ...
(Date:1/15/2017)... ... 2017 , ... Wondering where to go this Valentine's Day? Well, there is ... a romantic, lobster feast in the comfort of your own home. Lobster Gram is ... will be featured until February 15th, 2017. , Romantic Dinner one is Lobster ...
(Date:1/14/2017)... , ... January 14, 2017 , ... ... distinctions among their expanding line of activated charcoal products. With more and more ... of categorizing their products according to how they cater to specific needs. , ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... This morning, Stock-Callers.com draws attention ... fared at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... processes to develop technologies and products that combat debilitating ... hungry, use less and cleaner energy, and provide safer, ...
(Date:1/13/2017)...  Secretary of Health Karen Murphy today ... at Misericordia University and discussed the Wolf Administration,s efforts ... . "The opioid epidemic is the ... my professional career," Secretary Murphy said. "This area of ... by heroin and prescription opioid overdoses. Across the commonwealth ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... offering. ... fibrosis (CF) is a progressive genetic condition and is the result ... (CFTR) gene from both parents. The defective CFTR genes produce faulty ... buildup of a thick and sticky mucus in the lungs and ...
Breaking Medicine Technology: